Infant Bacterial Therapeutics AB (OSTO:IBT B) Days Payable : 0.00 (As of Mar. 2025)

View and export this data going back to 2016. Start your Free Trial

What is Infant Bacterial Therapeutics AB Days Payable?

Infant Bacterial Therapeutics AB's average Accounts Payable for the three months ended in Mar. 2025 was kr47.33 Mil. Infant Bacterial Therapeutics AB's Cost of Goods Sold for the three months ended in Mar. 2025 was kr0.00 Mil.

The historical rank and industry rank for Infant Bacterial Therapeutics AB's Days Payable or its related term are showing as below:

OSTO:IBT B's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 121.27
* Ranked among companies with meaningful Days Payable only.

Infant Bacterial Therapeutics AB's Days Payable stayed the same from Mar. 2024 (0.00) to Mar. 2025 (0.00). stayed the same

Infant Bacterial Therapeutics AB Days Payable Historical Data

The historical data trend for Infant Bacterial Therapeutics AB's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Infant Bacterial Therapeutics AB Days Payable Chart

Infant Bacterial Therapeutics AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Days Payable

Get a 7-Day Free Trial

Infant Bacterial Therapeutics AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Infant Bacterial Therapeutics AB's Days Payable

For the Biotechnology subindustry, Infant Bacterial Therapeutics AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Infant Bacterial Therapeutics AB's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Infant Bacterial Therapeutics AB's Days Payable distribution charts can be found below:

* The bar in red indicates where Infant Bacterial Therapeutics AB's Days Payable falls into.

Save Embed

;

Save Embed

;

Infant Bacterial Therapeutics AB Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Infant Bacterial Therapeutics AB's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as

	Days Payable (A: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2023 )	+	Accounts Payable (A: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2024 )	*	Days in Period
=	( (30.067	+	46.993)	/	2 )	/	0	*	365
=	38.53					/	0	*	365
=	N/A

Infant Bacterial Therapeutics AB's Days Payable for the quarter that ended in Mar. 2025 is calculated as:

	Days Payable (Q: Mar. 2025 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2024 )	+	Accounts Payable (Q: Mar. 2025 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2025 )	*	Days in Period
=	( (46.993	+	47.671)	/	2 )	/	0	*	365 / 4
=	47.332					/	0	*	365 / 4
=	N/A

Infant Bacterial Therapeutics AB Days Payable Related Terms

Thank you for viewing the detailed overview of Infant Bacterial Therapeutics AB's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Infant Bacterial Therapeutics AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (OSTO:IBT B) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

9IB:Germany

Address

Bryggargatan 10, Stockholm, SWE, 111 21

Website

https://www.ibtherapeutics.com

Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.

Infant Bacterial Therapeutics AB Headlines

No Headlines